United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 232,373 shares of the biotechnology company's stock after buying an additional 19,716 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.52% of United Therapeutics worth $81,990,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of UTHR. Wealthfront Advisers LLC grew its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the period. Norges Bank bought a new stake in United Therapeutics during the fourth quarter valued at $151,764,000. FMR LLC boosted its position in United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the period. Thrivent Financial for Lutherans grew its position in United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after purchasing an additional 189,967 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after purchasing an additional 161,751 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at $497,962.50. This represents a 69.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,500 shares of company stock worth $13,447,180 over the last ninety days. Corporate insiders own 10.30% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Finally, Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $392.00.

United Therapeutics Trading Down 1.4%

Shares of UTHR traded down $4.59 during midday trading on Friday, hitting $315.79. 126,237 shares of the company's stock traded hands, compared to its average volume of 440,902. The firm's fifty day moving average is $299.50 and its 200-day moving average is $335.89. United Therapeutics Co. has a 1 year low of $266.98 and a 1 year high of $417.82. The stock has a market capitalization of $14.24 billion, a price-to-earnings ratio of 13.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the previous year, the firm posted $6.17 EPS. The company's revenue for the quarter was up 17.2% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.